MedTrace Logo

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

NCT01022112 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 383

Last updated 2026-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.

Conditions

Interventions

DRUG

TA-7284-Low

TA-7284-Low

DRUG

TA-7284-Low-middle

TA-7284-Low-middle

DRUG

TA-7284-High-middle

TA-7284-High-middle

DRUG

TA-7284-High

TA-7284-High

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Nobuya Inagaki, M.D. · Kyoto University, Graduate School of Medicine

  • Kazuoki Kondo, M.D. · Tanabe Pharma Corporation

  • Tadashi Yoshida, M.D. · Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01022112 on ClinicalTrials.gov